Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire
On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second..
On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second..
Political anger and cynicism are rising in the United States and in many democracies worldwide, and both are associated with..
Phase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint, p =..